Shoshana-Shani Arami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shoshana-Shani Arami has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Marina Wax
National HIV-1 and Viral Hepatitis Reference Laboratory, Chaim Sheba Medical Center, Ramat Gan 5262112, Israel
1 shared publication - Mayan Yizchaki
Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Ramat Gan 5262112, Israel
1 shared publication - Neta S. Zuckerman
Central Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Center, Israel
1 shared publication - Or Kriger
Pediatric Infectious Disease Unit, The Edmond and Lily Safra Children’s Hospital, Chaim Sheba Medical Centre, Ramat Gan 52621, Israel
1 shared publication - Oran Erster
Israel Central Virology Laboratory of Ministry of Health, Sheba Medical Center , Ramat-Gan 5262100
1 shared publication - Orna Mor
Faculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel
1 shared publication
Latest Publications
- Open Access
Parvovirus B19 Outbreak in Israel: Retrospective Molecular Analysis from 2010 to 2023
This study presents an analysis of the epidemiological trends of parvovirus B19 (B19V) in Israel from 2010 to 2023, with particular emphasis on the outbreak in 2023. The analysis utilized molecular diagnostic data from individual patients obtained at the Central Virology Laboratory. Between 2010 and 2022, 8.5% of PCR-tested samples were positive for B19V, whereas in 2023, this percentage surged to 31% of PCR-tested samples. Throughout the study period, annual cycles consistently peaked in early spring/summer, with the most recent prominent outbreak occurring in 2016. Predominantly, diagnoses were made in children and women aged 20–39. Despite the notable surge in 2023, over 80% of positive cases continued to be observed in children and young women, with a decrease in cases during winter months. Furthermore, genotype 1a of the virus remained the predominant strain circulating during the outbreak. In light of these circumstances, consideration should be given to implementing screening measures, particularly among high-risk groups such as pregnant women.
Open AccessParvovirus B19 Outbreak in Israel: Retrospective Molecular Analysis from 2010 to 2023
This study presents an analysis of the epidemiological trends of parvovirus B19 (B19V) in Israel from 2010 to 2023, with particular emphasis on the outbreak in 2023. The analysis utilized molecular diagnostic data from individual patients obtained at the Central Virology Laboratory. Between 2010 and 2022, 8.5% of PCR-tested samples were positive for B19V, whereas in 2023, this percentage surged to 31% of PCR-tested samples. Throughout the study period, annual cycles consistently peaked in early spring/summer, with the most recent prominent outbreak occurring in 2016. Predominantly, diagnoses were made in children and women aged 20–39. Despite the notable surge in 2023, over 80% of positive cases continued to be observed in children and young women, with a decrease in cases during winter months. Furthermore, genotype 1a of the virus remained the predominant strain circulating during the outbreak. In light of these circumstances, consideration should be given to implementing screening measures, particularly among high-risk groups such as pregnant women.